Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Theratechnologies Inc. will report financial results and provide a business update for its fiscal 2023. They will also address the Complete Response Letter issued by the U.S. FDA for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and CEO, and other members of the management team. Participants are encouraged to join the call at least ten minutes in advance to secure access. Webcast and replay information is available on the company's website.
02/06/2024 - 07:30 AM
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.
Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin.
The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.
Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.
CONFERENCE CALL INFORMATION Conference Call Date February 21, 2024 Conference Call Time 8:30 a.m. EDT Webcast link https://edge.media-server.com/mmc/p/6fyph854 Dial in 1-888-317-6003 (toll free) or 1-412-317-6061 (international) Access Code 0664356 CONFERENCE CALL REPLAY Toll Free 1-877-344-7529 (US) / 1-855-669-9658 (Canada) International Toll 1-412-317-0088 Replay Access Code 3842515 Replay End Date February 28, 2024 To access the replay using an international dial-in number, please select this link:https://services.choruscall.com/ccforms/replay.html
An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’ .
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com , on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov . Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Philippe Dubuc Senior Vice President and Chief Financial Officerpdubuc@theratech.com 438-315-6608
When will Theratechnologies report financial results and provide a business update for fiscal 2023?
Theratechnologies will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.
What is the Complete Response Letter issued by the U.S. FDA for?
The Complete Response Letter was issued in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin.
Who will be hosting the call to provide the business update?
The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer, along with other members of the management team.
Where can participants find the webcast link and replay information?
The webcast link and replay information can be found on the Company’s Investor Relations website under ‘Past Events’.
THTX Rankings
#5441 Ranked by Stock Gains
THTX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Canada
City
Montreal
About THTX
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.